Figure 2

Dose-dependent repression of MSH3 expression in HdhQ111/+ mice following ICV MSH3 di-siRNA treatment. (A) RT-qPCR analysis of Msh3 mRNA levels in the striatum (STR), cortex (CTX), cerebellum (CER), and liver (LIV). (B) Representative Western blots and (C) quantitative analysis of MSH3 protein using densitometry in the striatum, cortex, cerebellum, and liver. Each sample has been analyzed on multiple independent blots. (D) RT-qPCR analysis of Msh6 and Msh2 mRNA levels in the striatum (E) quantitative analysis of MSH6 and MSH2 protein using densitometry in the striatum. Protein levels were normalized to β-actin and expressed as percentage of vehicle-treated mice. Error bars represent mean ± SD; n = 6–10 per group. One-Way ANOVA with Tukey’s post hoc analysis, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.